Skin Cancer
Conditions
Keywords
Actinic keratosis,, Cutaneous squamous cell carcinoma, mitochondria, metabolism
Brief summary
A collection of biological samples (skin) will be created to meet the objectives. Skin biopsies will be taken (excluding on face and fold), in accordance with standard practice.
Detailed description
Skin cancers are the most common type of cancer in human. Among them, cutaneous squamous cell carcinomas (cSCCs) represent the 2nd most frequent, with an incidence that continues to grow (+300% between 1994 and 2006) in line with the ageing of the population and sun exposure habits. cSCCs is a multi-stage carcinogenesis model: the pre-cancerous lesion is actinic keratosis (AK), which can either regress or progressively evolve into cSCC in situ and then infiltrating, and in some patients into a metastatic stage, initially lymph node and then distant, life-threatening. cSCCs are classified as low-risk or high-risk according to clinical and histological criteria associated with the risk of recurrence and metastasis. However, there is currently no tool for predicting this risk for a given cSCC, particularly according to its genetic characteristics. Indeed, the high mutation rate makes it difficult to identify specific genetic profiles. Similarly, there is no tool to predict the potential for a precancerous lesion (AK) to regress or to develop into a cSCC. The aim of this study is to characterize the molecular and metabolic features as well as immunologic landscapes of precancerous AK and cSCCs in order to uncover epithelial and immune cell subpopulations supporting tumor progression.
Interventions
PROCEDUREskin biopsies
Additional punches of 3 mm from a skin lesion part of a skin biopsy performed as part of routine care, an additional (optional) biopsy of healthy skin
Sponsors
Institut National de la Santé Et de la Recherche Médicale, France
University Hospital, Bordeaux
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients aged 18 or over, * Patients with suspected AK, or cSCC lesions (in situ, infiltrating or metastatic), * Patients able to sign a consent form, * Patients affiliated to a French Social Security system.
Exclusion criteria
* Patients who have previously received systemic treatment (chemotherapy, immunotherapy), * Patients with cSCC or AK localized on visible zone of the face or folds * Patients under guardianship or guardianship, * Patient not affiliated to a French Social Security system.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Relative abundance of metabolite and differential enzyme expression in tumor lesion versus healthy tissue | Day 1 | Evaluation of metabolic changes involved in cSCC progression |
| Percentages of individual immune cell populations among total tumor-infiltrating immune cells will be evaluated. | Day 1 | Characterization of the immune cells infiltrate Expression of multiple immune cell markers will be assessed in samples from different subtypes of cSCC by single cell RNA sequencing. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| percentage of samples in each category (AK, in situ, ...) that present differentiation features are assessed by immunostaining of loricrin, filaggrin, K10 | Day 1 | Evaluation of skin differentiation markers |
| percentage of samples expressing aggressive markers will be assessed by evaluating the proliferation index | Day 1 | Evaluation of cSCC aggressiveness markers with the percentage of samples expressing aggressive markers will be assessed by evaluating the proliferation index, degree of differentiation, invasion beyond subcutaneous fat, perineural invasion, vascular invasion level of infiltration following immunohistochemistry analyses on formalin-fixed paraffin-embedded tissue sections. |
| percentage of samples that are highly proliferative will be calculated by measuring the ability of colony formation (SRB Test) | Day 1 | Evaluation of cancer proliferative features on skin biopsies with percentage of samples that are highly proliferative will be calculated by measuring the ability of colony formation (SRB Test) and cell cycle progression (flow cytometer, western). |
Countries
France
Contacts
Primary ContactMarie BEYLOT-BARRY, MD, PhD
Backup ContactChristine ALFARO
Outcome results
None listed